Lixte Biotechnology Holdings- Warrants (01/01/2025) P/E Ratio

The latest P/E ratio for LIXTW is -3.56. That is below the Healthcare sector average of 70.94. Investors often review this figure alongside Lixte Biotechnology Holdings- Warrants (01/01/2025)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, LIXTW currently prints -3.56 for P/E ratio, while the sector average sits near 70.94. That is roughly 105.0% below the sector mean. Large gaps often invite a closer look at Lixte Biotechnology Holdings- Warrants (01/01/2025)'s growth, margins, and balance sheet.

A P/E ratio of -3.56 for Lixte Biotechnology Holdings- Warrants (01/01/2025) is not 'good' or 'bad' on its own. Compare it with the peer average (70.94) and with LIXTW's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting LIXTW's P/E ratio (-3.56), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Lixte Biotechnology Holdings- Warrants (01/01/2025)'s P/E ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.